Johnson & Johnson
The size of the Indian medical devices market is estimated at Rs. 90,000 crore (US$ 11 billion) in 2022 and is expected to grow to US$ 50 billion by 2030 with a CAGR of 16.4 %.
Established in 1957, Johnson & Johnson is a leading healthcare manufacturer in the world. The company offers products across three business segments as follows:
Medical Devices: With presence in this category for over 60 years, it is the leading medical devices company in India with products dedicated to addressing unmet needs in the fields of orthopaedics, cardiovascular disease, coronary artery disease, peripheral vascular and obstructive disease, neurovascular disease, arrhythmias, diabetes care, bariatric and metabolic surgery, cancer surgery, vision care, general surgery, urologic surgery, hernia surgery and infection prevention.
Pharmaceuticals: Johnson & Johnson’s pharmaceutical reach is spread across medical fields of oncology, immunology, neuroscience and analgesia, dermatology, infectious diseases and metabolic diseases.
Consumer Healthcare: Johnson & Johnson offers consumer healthcare products in baby care, feminine hygiene, face care, OTC, oral care and wound care. The company has some iconic brands in this segment such as Johnson’s Baby, Stayfree, Clean & Clear and BAND-AID.
- The largest medical devices division in India.
- Has over 134,400 employees worldwide; employs >3,500 people in India.
| Year | Milestone |
|---|---|
| 2023 |
Johnson & Johnson retains its position on Fortune's Most Admired Companies list for the 22nd year, ranking 2 in Pharmaceuticals and 27 overall, affirming its enduring excellence and industry leadership. In December 2023, Johnson & Johnson submitted a supplemental biologics license application and a new drug application to the U.S. FDA, seeking approval of RYBREVANT® (amivantamab-vmjw) plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC). In November 2023, Johnson & Johnson MedTech acquired Laminar, Inc., for an upfront payment of US$ 400 million. Laminar is a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). In July 2023, Johnson & Johnson Private Limited announced the appointment of Mr. Anuj Virmani as the Managing Director for its Johnson & Johnson MedTech India division. |
| 2022 |
As informed in March 2022, Stayfree in association with UNICEF, educated over 1.7 million girls on Menstrual Hygiene Management (MHM) in the last seven years. |
| 2021 |
In August 2021, Johnson & Johnson’s single-dose COVID-19 vaccine received emergency-use approval in India. In June 2021, the company announced that it is in talks with the Indian government to launch its single-shot COVID-19 vaccine. |
| 2015 |
Entered a public–private partnership with the National Institute of Pharmaceutical Education and Research (NIPER) in Ahmedabad, India, for a postgraduate training programme for future medical devices industry regulators. |
| 1975 |
Ethnor Ltd. (merged with Johnson & Johnson in 1994) established a manufacturing plant for pharmaceutical and ethical products. Johnson & Johnson’s ‘Vicryl’ suture enters the Indian market. |
| 1962 |
Established its first medical devices (sutures) manufacturing facility in Mumbai (then Bombay), India. |
| 1959 |
Established its first consumer products manufacturing facility in Mumbai (then Bombay), India. |
| 1957 |
Incorporated as a single legal entity in India. Launched three business segments namely medical devices, consumer products and pharmaceuticals. |
| 1947 |
Expanded its global presence in India with brands such as Johnson’s Baby Powder. |
Partners
